Formycon AG develops high-quality biosimilars, focusing on therapies in ophthalmology and immunology, among other significant chronic diseases. Their activities range from technical-pharmaceutical development to clinical studies and the preparation and submission of regulatory documents.

Formycon AG

HSTS

Google Font API

Font Awesome

nginx

GStatic Google Static Content

PostalAddress Schema

WPForms

Place Schema

German Server Location

WordPress Multisite

Operations

Mauro Sergi

Risk, Safety, Compliance

Andrey Mladenov

Clinical Development Manager

Andrey Trukhmanov

Regulatory Affairs CMC Senior Manager

Bianca-Sabrina Targosz

Human Resources

Birgit Thomas

Jessy Wunderlich

Regulatory Affairs Manager

Katalin Varga

Manager Regulatory Affairs, Regulatory Affairs CMC Analytics

Nermina Vejzagic

Global Project Leader

Smita Thobhani

Sven Brenner

Carsten Brockmeyer

European Union (EU) Public Companies With More Than 100 Employees

European Union (EU) Public Companies With Less Than $1B in Revenue

Europe, Middle East, and Africa (EMEA) Companies that Exited (Top 10K)

Germany Companies With Less Than $500M in Revenue (Top 10K)

Formycon GmbH is more than a regular CRO that provides formulation and analytical services to the biopharmaceutical industry. The complete analytical development chain – starting from protein characterization and comparability studies up to GMP Quality Control and stability testing of clinical study and market medication. The Formulation one-stop shop – Formycon covers pre-formulation, development of systemic and local, liquid, freeze-dried and sustained release drug product formulations, supply of pre-clinical studies and development of the manufacturing process.

Richter Group

Post-IPO Equity - Formycon

Bavarian Research Foundation

Grant - Formycon

Martinsried

Bayern

Germany

Europe

Formycon

Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard

FDA grants approvals to Stelara, Neupogen, Eylea biosimilars

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi

Classification of First Berlin Equity Research GmbH to Formycon AG

Formycon reports a strong first half-year with multiple m...

Formycon announces start of clinical phase III trial for Keytruda

Formycon and Fresenius Kabi receive positive CHMP opinion...

Formycon receives FDA approval for FYB203/AHZANTIVE

Formycon reports on the results of the Annual General Meeting

Original-Research: Formycon AG (von First Berlin Equity R...

India

Asia

Algeria

Africa

HTML5

Office 365

Microsoft Outlook

jQuery

Google Analytics

Wordpress

Google Maps API

Vimeo

Apache Server

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 1, 2024 1:34 AM	8f4754bd
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 1, 2024 1:34 AM	34a98d0b
crunchbase trigger	general	Nov 12, 2024 12:52 PM	a0c869c7
crunchbase profile	general	Nov 12, 2024 10:51 PM	cc701518
li profile	general
translate crunchbase fundingrounds	general	Nov 12, 2024 11:54 PM	e4f3fa17
peers	general	Oct 1, 2024 1:34 AM	1a26e5c4
news basic	general	Oct 1, 2024 1:34 AM	386e455b
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:FORMYCON

Formycon AG

Last Close

46.85

25/11 09:20

Market Cap

965.83M

Beta: -

Volume Today

519

Avg: -